Different Doses of ZED1227 vs. Placebo in NAFLD

Summary

This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 20, 50, or 100 mg ZED1227 vs. placebo for the treatment of patients with NAFLD with fibrosis.

Timeline

Start

2022-04-19

Primary completion

2023-06-07

Completion

2023-07-05

Drugs

Indications